Merck & Co., Inc.

6MK.DE·XETRA·Healthcare
Compare
132.46+0.46 (+0.35%)today
At close: Oct 21, 5:35 PM CEST · May be delayed up to 15 min · EUR

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close132.00
Open131.32
Day range130.96132.66
52-week range71.30135.06
Off day high−0.15%
Off 52-week high−1.93%
Volume776
Avg. volume (3M)1.52K
Market cap326.80B
EPS (TTM)1.08
Forward P/E—
P/E ratio (TTM)122.65
Dividend yield2.29% (3.02)
Beta (5Y)0.22
Shares outstanding2.47B
Short interest—
Earnings dateOct 29, 2026
Analyst target—
Profit margin4.77%

Against its peers

Compare in full ›
6MK.DE AZN PFE NVS GSK JNJ
Market cap 326.80B 261.25B 170.14B 292.58B 100.22B 621.22B
P/E (TTM) 122.6 25.2 39.3 23.3 15.8 39.1
Forward P/E — 14.9 10.3 15.7 10.2 22.2
Price/book 8.7 5.2 2.0 7.0 4.3 7.3
Dividend yield 2.29% 1.90% 5.71% 3.09% 3.59% 2.07%
1-year change +73.00% +1.17% +21.80% +16.90% +14.39% +34.43%
Today +0.35% −0.22% −0.86% +0.19% −1.20% −0.61%

The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.

Latest news

All 6MK.DE news ›
pharmaphorum·

Merck buys Silence and its siRNA pipeline for $1.3bn

Merck KGaA has reached a deal to acquire UK-based Silence Therapeutics in ​an all-cash, $1.3 billion deal that will boost its presence in RNA-focused drugs and give it a late-stage drug candidate for rare disease polycythemia vera (PV).…

Seeking Alpha·Positive

Merck KGaA to buy Silence Therapeutics in all-cash deal

Merck KGaA to acquire Silence Therapeutics for $1.3B cash, a 130% premium, boosting siRNA pipeline and rare-disease focus. Merck KGaA (MKGAY) (MKGAF) has agreed to acquire Silence Therapeutics (SLN) in an all-cash deal with an enterprise…

TIKR.com·Positive

Better Dividend Stock: Merck vs. Bristol Myers Squibb

Pressmaster from Pressmaster and Ri_Ya from pixabay Merck (MRK) and Bristol Myers Squibb (BMY) both raised their 2026 sales outlooks this summer. That’s good news for income investors, since a growing business keeps a dividend growing. The…

medwatch.com·

Merck buys biotech Silence Therapeutics for USD 1.1bn

Senior Drug Product Filling Specialist Associate Market Access Director – International Markets Senior Drug Substance Scientist Head of Medical Affairs International Markets Chef for Kvalitet og Compliance Head of Clinical Operations…

TIKR.com·Positive

Merck vs. Amgen: Which Dividend Stock Pays You More in 10 Years?

AtlasStudio from Getty Images via Canva On Aug. 4, Merck (MRK) raised and narrowed its 2026 sales outlook to $66.3 billion to $67.3 billion. The same day, Amgen (AMGN) reported second-quarter revenue up 10% to $10.1 billion. For income…

From articles in the 4Search news index.

In the news

183mentions in 30 days
183with it in the headline
Positivesentiment

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use.